The German Lipoprotein Apheresis Registry—Summary of the ninth annual report
Volker Schettler, Christian Peter, Thomas Zimmermann, Ulrich Julius, E. Roeseler, Georg Schlieper, Franz Heigl, P. Grützmacher, Iris Löhlein, Reinhard Klingel, Bernd Hohenstein, Wolfgang Ramlow, Anja Vogt, for the Scientific Board of GLAR for the German Apheresis Working Group
Abstract
During 2012-2020, 89 German apheresis centers collected retrospective and prospective observational data of 2028 patients undergoing regular lipoprotein apheresis (LA) for the German Lipoprotein Apheresis Registry (GLAR). More than 47 500 LA sessions are documented in GLAR. In 2020, all patients treated with LA showed a high immediate median reduction rate of LDL-C (68.2%, n = 1055) and Lp(a) (72.4%, n = 994). Patient data were analyzed for the incidence rate of major coronary events (MACE) 1 and 2 years before the beginning of LA treatment (y-2 and y-1) and prospectively up to 7 years on LA (y + 1 to y + 7). During the first 2 years of LA (y + 1 and y + 2), a MACE reduction of 78% was observed. Current analysis of GLAR data shows very low incidence rates of cardiovascular events in patients with high LDL-C and/or high Lp(a) levels, progressive ASCVD, and maximally tolerated lipid lowering medication regular by LA results.